Improving kidney transplant outcomes in teens and young adults
Treatments studied
Part of Kidney & urinary clinical trials.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 13 and 20 years old.
- This will be your first kidney transplant.
- You have had Epstein-Barr virus (EBV) in the past, confirmed by a blood test.
- You do not have active infections, cancer, or certain kidney diseases that can come back after transplant.
- You are up to date on vaccines (unless a doctor says it's not safe for you).
- You agree to use birth control if you could become pregnant or get someone pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
This trial looks at replacing standard anti-rejection medicines (tacrolimus, a type of CNI, plus mycophenolate and possibly prednisone) with belatacept in adults who have early kidney graft dysfunction 3–12 months after a kidney transplant. It aims to see if belatacept can control rejection and protect kidney function in the right patients.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial tests if giving you back specially grown immune cells (called Tregs) made from your own blood can help your body accept a new kidney from a living donor with less rejection. It is for people who are ready for a first kidney transplant.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.